Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP: DMTTF )

0.1013 -0.0043 (-4.07%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 153,487
Open 0.1090
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1056
Today's Range 0.1006 - 0.1094
52wk Range 0.0550 - 0.3328
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings
Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major... 
Via Benzinga
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental 
Via PressReach

Performance

YTD
+38.77%
+38.77%
1 Month
+42.68%
+42.68%
3 Month
-25.51%
-25.51%
6 Month
-5.50%
-5.50%
1 Year
-39.05%
-39.05%

More News

Read More
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
From Small Pharma Inc.
Via Globe NewsWire
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
From Small Pharma Inc.
Via Globe NewsWire
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
From Small Pharma Inc.
Via Globe NewsWire
Comparing Psychedelics' Administration Routes: Are Intramuscular Injections More Effective Than Intravenous?
Via Benzinga
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
From Small Pharma Inc.
Via Globe NewsWire
Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More
Via Benzinga
This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage
Via Benzinga
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
From Small Pharma Inc.
Via Globe NewsWire
Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing
Via Benzinga
How Certain Psychedelics Produce Brain And Behavior Changes: UCL Leads New Study
Via Benzinga
First Patient Dosed in Small Pharma’s Drug Interaction Study
From Small Pharma Inc.
Via Globe NewsWire
Small Pharma To Support University College London Research Project on Neuroplasticity
From Small Pharma Inc.
Via Globe NewsWire
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
From Small Pharma Inc.
Via Globe NewsWire
Psychedelic Stock Gainers And Losers From November 24, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From November 23, 2022
Via Benzinga
Small Pharma to Participate in November Investor and Healthcare Conferences
From Small Pharma Inc.
Via Globe NewsWire
Psychedelic Stock Gainers And Losers From November 8, 2022
Via Benzinga
Compass Pathways, Allied Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From November 3, 2022
Via Benzinga
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today
Via Benzinga
This Novel Short-Acting Psychedelic Compound Is Ready For First Phase 1 Clinical Try-Out
Via Benzinga
Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028
From Small Pharma Inc.
Via Globe NewsWire
Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.